Company: INMB
Filing Date: 2025-06-30
Form Type: 424B5
Source: 0001213900-25-059298
Chunk: 12

Company: Inmune Bio, Inc.
Filing Date: 2025-06-30
Form: 424B5
Chunk 12
---
 the fiscal year ended December 31,
2024, as updated by annual, quarterly and other reports and documents we file with the SEC, as well as those discussed elsewhere in this
prospectus supplement, and the following factors:

| ● | volatility or decline of our stock price, or absence of stock price appreciation;                                                                  |
| ● | fluctuation in quarterly results;                                                                                                                  |
| ● | our failure to earn revenues or profits;                                                                                                           |
| ● | the success of our product research and development programs;                                                                                      |
| ● | inadequate capital to continue or expand its business, and the inability to raise additional capital or financing to implement its business plans; |
| ● | reductions in demand for our products and services, whether because of competition, general industry conditions or other reasons;                  |
| ● | litigation with or legal claims and allegations by outside parties;                                                                                |
| ● | insufficient revenues to cover operating costs, resulting in persistent losses;                                                                    |
| ● | regulatory and personnel issues;                                                                                                                   |
| ● | the introduction of technological innovations or new commercial products by our competitors, and competitive developments in the relevant markets; |
| ● | the outcome of any legal proceedings in which we are involved or in which we may in the future become involved;                                    |
| ● | the effects of public health crises, pandemics and epidemics, such as the COVID-19 pandemic; and                                                   |
| ● | other risks and uncertainties detailed from time to time in our SEC filings.                                                                       |

We urge you to consider these
factors carefully in evaluating the forward-looking statements contained in this prospectus supplement. All subsequent written or oral
forward-looking statements attributable to our company or persons acting on our behalf are expressly qualified in their entirety by these
cautionary statements. The forward-looking statements included in this prospectus supplement are made only as of the date of this prospectus
supplement. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future
events or otherwise, except to the extent that we are required to do so by law.

<div align='center'>S-6

USE OF PROCEEDS</div>

We estimate that the net proceeds
from this offering, after Placement Agent fees and estimated offering expenses payable by us, will be approximately $17.4 million.

Unless otherwise indicated
in a prospectus supplement, we intend to use the net proceeds from this offering for general corporate purposes and working capital.

<div align='center'>S-7